Publications by authors named "Susan Lyerly"

Claim this Profile
R
Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.
Daniel R Reed, Margaux Wooster, Scott Isom, Leslie R Ellis, Dianna S Howard, Susan Lyerly

Ann Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Rebecca Anderson, Lance D Miller, Scott Isom, Jeff W Chou, Kristin M Pladna, Susan Lyerly

Nat Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.
Kavya K Kannan, Paz Vellanki, Scott Isom, Bernard Tawfik, Allison Winter, Susan Lyerly

Leuk Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of 10-day decitabine in acute myeloid leukemia.
Ian M Bouligny, Vivek Mehta, Scott Isom, Leslie R Ellis, Rupali R Bhave, Susan Lyerly

Leuk Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Mary Beth Seegars, Ryan Woods, Leslie R Ellis, Rupali Roy Bhave, Dianna S Howard, Susan Lyerly

J Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study.
Samuel J Yates, Susan Lyerly, Megan Manuel, Janet A Tooze, Heidi D Klepin

Cancer Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Timothy S Pardee, Rebecca G Anderson, Kristin M Pladna, Scott Isom, Lais P Ghiraldeli, Susan Lyerly

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.
Tamjeed Ahmed, Abby L Koch, Scott Isom, Heidi D Klepin, Jonathan M Bishop, Susan Lyerly

Leuk Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Tamjeed Ahmed, Scott Holwerda, Heidi D Klepin, Scott Isom, Leslie R Ellis, Susan Lyerly

Leuk Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Timothy S Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Susan Lyerly

Clin Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Bernard Tawfik, Sarunas Sliesoraitis, Susan Lyerly, Heidi D Klepin, Julia Lawrence

Ann Hematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis